The FDA’s Graphic Tobacco Warning and the First Amendment by Orentlicher, David
Scholarly Commons @ UNLV Law
Scholarly Works Faculty Scholarship
2013
The FDA’s Graphic Tobacco Warning and the First
Amendment
David Orentlicher
University of Nevada, Las Vegas -- William S. Boyd School of Law
Follow this and additional works at: http://scholars.law.unlv.edu/facpub
Part of the First Amendment Commons, Health Law and Policy Commons, and the Medical
Jurisprudence Commons
This Article is brought to you by the Scholarly Commons @ UNLV Law, an institutional repository administered by the Wiener-Rogers Law Library at
the William S. Boyd School of Law. For more information, please contact david.mcclure@unlv.edu.
Recommended Citation
369 New Eng. J. Med. 204 (2013).
PERSPECTIVE
n engl j med 369;3 nejm.org july 18, 2013204
Tobacco Use among Homeless People
tels in Canada: 11 year follow-up study. BMJ 
2009;339:b4036.
3. Arnsten JH, Reid K, Bierer M, Rigotti N. 
Smoking behavior and interest in quitting 
among homeless smokers. Addict Behav 
2004;29:1155-61.
4. Apollonio DE, Malone RE. Marketing to 
the marginalised: tobacco industry targeting 
of the homeless and mentally ill. Tob Control 
2005;14:409-15.
5. Baggett TP, Anderson RH, Freyder PJ, et al. 
Addressing tobacco use in homeless popula-
tions: a survey of health care professionals. 
J Health Care Poor Underserved 2012;23: 
1650-9.
DOI: 10.1056/NEJMp1301935
Copyright © 2013 Massachusetts Medical Society.
The FDA’s Graphic Tobacco Warnings and the First 
Amendment
David Orentlicher, M.D., J.D.
In the past, constitutional prin-ciple gave the government broad 
authority to regulate tobacco or 
pharmaceutical advertising. The 
state’s power to safeguard the pub-
lic health was strong, and compa-
nies’ freedom to plug their prod-
ucts was weak.
But the Supreme Court has 
changed course. Whereas it once 
did not view “commercial” speech 
as the kind of speech the First 
Amendment protects, it now gives 
businesses nearly the same rights 
to market their goods as it does 
individuals to speak their minds. 
And as the Court has broadened 
corporate freedom to advertise, 
it has narrowed governmental 
power to preserve the public’s 
health. Whereas the Court once 
gave the government more lee-
way when invoking its interests in 
public health than when asserting 
other state interests, it now tends 
to hold health-related rules to the 
same constitutional standards as 
other types of rules.1
As a result, government today 
is much more susceptible to chal-
lenge when it tries to regulate 
the promotional activities of the 
tobacco or pharmaceutical indus-
try. In 2011, the Supreme Court 
rejected Vermont’s effort to re-
strict the use of prescription data 
by drug companies’ sales repre-
sentatives.2 And last year, the U.S. 
Court of Appeals for the D.C. 
Circuit vetoed the new graphic 
warnings for cigarette packages 
that had been issued by the Food 
and Drug Administration (FDA).3 
The Supreme Court’s increasing 
sympathy for corporate speech 
and decreasing deference to pub-
lic health authorities makes it 
more difficult for government to 
protect the public’s health. The 
fate of the graphic cigarette warn-
ings is illustrative.
Congress authorized the graph-
ic warnings when it passed the 
Family Smoking Prevention and 
Tobacco Control Act in 2009. 
The Act requires the use of nine 
new textual warnings for ciga-
rette packages and directs the 
Department of Health and Human 
Services to select color graphics 
to accompany the warnings. The 
images have to depict the “nega-
tive health consequences” of 
smoking, with text and graphic 
taking up the top halves of each 
pack’s front and back panels.
In June 2011, the FDA unveiled 
the nine images, including some 
that were quite explicit. One 
 image showed a man smoking 
through a tracheostomy (see im-
age). Another showed the corpse 
of a man with staples in his 
chest on an autopsy table. Sever-
al tobacco companies promptly 
sued, alleging that the graphic-
warning requirements violated 
their First Amendment rights. 
The companies prevailed in both 
the district court and the D.C. 
Circuit.
In one sense, the result was 
not surprising, given the Supreme 
Court’s increased sympathy to-
ward corporations and their First 
Amendment rights. Regulations 
of commercial speech often suc-
cumb to judicial scrutiny.
However, there was good rea-
son to think that the D.C. Circuit 
would uphold the graphic warn-
ings. Even as the Supreme Court 
has narrowed the power of gov-
ernment to regulate corporate 
speech, it has preserved an impor-
tant authority to regulate. The 
graphic warnings seemed to fall 
within that authority.
The preserved authority re-
flects the distinction the Supreme 
Court makes between the regula-
tion of corporate speech that in-
forms and the regulation of cor-
porate speech that misinforms. 
On the one hand, the Court usu-
ally objects when the government 
tries to block truthful speech by 
businesses. In the prescription-
data case, the Vermont law would 
have restricted the free flow of 
information about physicians’ 
prescribing practices. On the oth-
er hand, the Court typically ap-
proves when the government tries 
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to prevent false or deceptive 
speech by businesses. For exam-
ple, the government may forbid 
companies from saying things 
that are not true. It also may re-
quire companies to make disclo-
sures that will  allow consumers 
to make informed choices and 
not be misled by advertising 
hype. Common disclosure re-
quirements include the corporate 
prospectus for stock offerings, 
the total interest payments for a 
home mortgage, nutritional in-
formation for foods, and the tex-
tual warnings for cigarettes.
The graphic cigarette warn-
ings appeared to serve purposes 
similar to those of other required 
disclosures. The warnings would 
promote understanding of the 
risks of smoking and prevent 
people from being misled by 
cigarette marketing.
Indeed, the U.S. Court of Ap-
peals for the Sixth Circuit had 
upheld Congress’s authority to 
mandate graphic warnings.4 As 
that court observed, people of-
ten do not read textual warnings 
on cigarette packages. And even 
when read, the warnings may 
not be effective in informing 
consumers about the risks to 
their health. Adding color imag-
es can ensure that textual warn-
ings are noticed, read, and under-
stood. Sometimes a picture really 
is worth a thousand words.
Even though the Supreme Court 
let the Sixth Circuit’s decision 
stand, its effect is limited. The 
Sixth Circuit considered only 
whether Congress may require 
some graphic warnings. The D.C. 
Circuit considered the consti-
tutionality of the FDA’s actual 
warnings.
In rejecting the warnings by 
a two-to-one vote, the D.C. Circuit 
identified two problems. First, 
the majority did not think the 
images were needed to prevent 
cigarette companies from mis-
leading consumers. Other statu-
tory provisions already prohibited 
many kinds of deceptive labeling 
or advertising. The court was 
not willing to defer to the FDA’s 
judgment that the new images 
were necessary. Second, the warn-
ings were not designed simply to 
ensure that consumers fully un-
derstand the risks to their health 
from cigarettes. Instead, wrote the 
majority, the warnings would pri-
marily serve to convey the gov-
ernment’s antismoking message. 
Indeed, each of the new images 
would include the phone num-
ber for the National Cancer In-
stitute’s tobacco cessation hot-
line, 1-800-QUIT-NOW. Whereas 
government may use its own re-
sources to publicize its perspec-
tives, it generally may not force 
individuals or corporations to 
spend their dollars to disseminate 
its viewpoint.
Rather than seek Supreme 
Court review of the D.C. Cir-
cuit’s decision, the FDA opted to 
return to the drawing board and 
develop new graphic warnings. 
In the meantime, we are left 
with some important questions.
First, when do graphic warn-
ings cross the line between try-
ing to inform and trying to per-
suade? Does it depend on how 
“shocking” or how prominent 
they are? Two of the three D.C. 
Circuit judges thought that the 
images were designed to evoke 
an emotional response rather than 
to convey factual information. 
The dissenting judge cited the 
FDA’s point that warnings more 
effectively communicate infor-
mation when they elicit a strong 
emotional reaction. In addition, 
the images would provide infor-
mation about risk when viewed 
in conjunction with their ac-
companying text. For example, 
the image of the man smoking 
through a tracheostomy accom-
panied the warning “Cigarettes 
are addictive” and would have il-
lustrated the tenacity of nicotine 
addiction. In the dissenter’s view, 
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the images would have been ac-
ceptable without the cessation 
hotline number.
Second, must the warnings 
correct misleading impressions 
from the company’s cigarette 
packaging or current advertise-
ments, or may they also correct 
misimpressions from past pro-
motional materials?
Third, if courts will not defer 
to the judgment of public health 
authorities about the need for 
disclosure mandates, what kind 
of empirical evidence must the 
FDA present in order to justify 
the use of graphic warnings?
Whatever the answers to these 
questions, companies today are 
better able to promote their prod-
ucts, and government is less able 
to promote health than was the 
case in the past. Ironically, early 
protection of commercial speech 
rested in large part on the need 
to serve consumers’ welfare. In 
1976, for example, the Supreme 
Court struck down a Virginia law 
that prevented pharmacists from 
advertising their prices for pre-
scription drugs.5 The law espe-
cially hurt persons of limited 
means, who were not able to shop 
around and therefore might not 
be able to afford their medicines. 
Today, by contrast, courts are us-
ing the First Amendment to the 
detriment of consumers’ welfare, 
by invalidating laws that would 
protect the public health.
Disclosure forms provided by the author 
are available with the full text of this arti-
cle at NEJM.org.
From the Hall Center for Law and Health, 
Indiana University Robert H. McKinney 
School of Law, and the Indiana University 
School of Medicine — both in Indianapolis.
This article was published on June 26, 2013, 
at NEJM.org.
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The FDA and Graphic Cigarette-Pack Warnings —  
Thwarted by the Courts
Ronald Bayer, Ph.D., David Johns, B.A., and James Colgrove, Ph.D.
On August 24, 2012, in R.J. Reynolds Tobacco Company v. 
Food and Drug Administration, the 
U.S. Court of Appeals for the 
District of Columbia ruled that 
the regulations proposed by the 
Food and Drug Administration 
(FDA) mandating the inclusion of 
graphic warnings on cigarette 
packs (see photo) violated the 
First Amendment: they would 
compel companies to express 
antitobacco messages on their 
own dime. Seven months later, 
on March 14, 2013, the Depart-
ment of Justice announced that 
the government would not appeal 
that decision to the Supreme 
Court.
In explaining the decision not 
to defend the regulations, which 
had been developed pursuant to 
congressional mandate under the 
2009 Family Smoking Prevention 
and Tobacco Control Act, Attorney 
General Eric Holder stated that 
the FDA would “undertake re-
search to support a new rulemak-
ing consistent with the Tobacco 
Control Act.” If new graphic 
warnings that emerged from the 
process were also deemed uncon-
stitutional, “there will be an op-
portunity to seek full Supreme 
Court review at that time.”1 How-
ard Koh, Assistant Secretary for 
Health, described the setback in 
cautious language: “Although we 
pushed forcefully for graphic 
health warning labels to appear 
on cigarette packages, the D.C. 
Circuit’s ruling against the warn-
Whereas the Court once gave the government 
more leeway when invoking its interests  
in public health than when asserting other  
state interests, it now tends to hold  
health-related rules to the same constitutional 
standards as other types of rules.
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